TABLE 1.

Demographic and clinical data^a

Patient group (mean age [yrs] ± SD)	Patient ID	Patient sex	Clinical form at treatment initiationb	Clinical formb at 48 mo after treatment	Progression to cardiac form or cardiac form worsening?b	Hemoculture for T. cruzi 60 days after treatment	Hemoculture for T. cruzi 48 mo after treatment	Age (yrs) at 48 mo after treatment
4 males/4 females (53.1 ± 6.6)	P1	Male	Indeterminate	Indeterminate	No	Negative	Negative	42
	P2	Female	Indeterminate	Indeterminate	No	Negative	Negative	53
	P3	Female	Indeterminate	Indeterminate	No	Negative	Negative	61
	P4	Male	Indeterminate	Indeterminate	No	Negative	Negative	62
	P5	Male	Indeterminate	Indeterminate	No	Negative	Negative	56
	P6	Female	Indeterminate	Indeterminate	No	Negative	Negative	49
	P7	Male	Indeterminate	Indeterminate	No	Negative	Negative	53
	P8	Female	Indeterminate	Indeterminate	No	Negative	Negative	49
5 males/4 females (55.3 ± 10.6)	P9	Male	Cardiac	Cardiac	No	Negative	Negative	66
	P10	Male	Indeterminate	Cardiac	Yes	Negative	Negative	37
	P11	Male	Cardiac	Cardiac	No	Negative	Negative	65
	P12	Female	Indeterminate	Cardiac	Yes	Negative	Negative	44
	P13	Male	Cardiac	Cardiac	Yes	Negative	Negative	58
	P14	Female	Cardiac	Cardiac	No	Negative	Negative	65
	P15	Female	Indeterminate	Cardiac	Yes	Negative	Negative	46
	P16	Male	Cardiac	Cardiac	Yes	Negative	Negative	62
	P17	Female	Cardiac	Cardiac	No	Negative	Negative	55

^aAll patients were subjected to the following treatment regimen (according to guidelines from the 2nd Brazilian Consensus on Chagas Disease, 2016): benznidazole administered at 5 mg/kg of body weight for 60 days, three doses/day; maximum daily dose, 300 mg. P value, >0.99 (by Fisher's exact test) for patient sex; P value, 0.62 (by Student’s t test) for age. ID, identifier.

^bData were determined according to guidelines from the 2nd Brazilian Consensus on Chagas Disease, 2016.